GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (FRA:0PQ) » Definitions » Cyclically Adjusted Price-to-FCF

ProQR Therapeutics NV (FRA:0PQ) Cyclically Adjusted Price-to-FCF : (As of Sep. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ProQR Therapeutics NV Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF falls into.



ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

ProQR Therapeutics NV's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, ProQR Therapeutics NV's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.08/129.9100*129.9100
=-0.080

Current CPI (Jun. 2024) = 129.9100.

ProQR Therapeutics NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -0.586 99.960 -0.762
201412 -0.241 99.050 -0.316
201503 -0.236 99.750 -0.307
201506 -0.278 100.230 -0.360
201509 -0.271 100.500 -0.350
201512 -0.299 99.730 -0.389
201603 -0.354 100.310 -0.458
201606 -0.424 100.260 -0.549
201609 -0.480 100.570 -0.620
201612 -0.316 100.710 -0.408
201703 -0.376 101.440 -0.482
201706 -0.412 101.370 -0.528
201709 -0.302 102.030 -0.385
201712 -0.304 101.970 -0.387
201803 -0.304 102.470 -0.385
201806 -0.176 103.100 -0.222
201809 -0.131 103.950 -0.164
201812 -0.235 103.970 -0.294
201903 -0.324 105.370 -0.399
201906 -0.282 105.840 -0.346
201909 -0.226 106.700 -0.275
201912 -0.257 106.800 -0.313
202003 -0.305 106.850 -0.371
202006 -0.217 107.510 -0.262
202009 -0.201 107.880 -0.242
202012 -0.237 107.850 -0.285
202103 -0.232 108.870 -0.277
202106 -0.152 109.670 -0.180
202109 -0.121 110.790 -0.142
202112 0.050 114.010 0.057
202203 -0.290 119.460 -0.315
202206 -0.211 119.050 -0.230
202209 -0.219 126.890 -0.224
202212 -0.246 124.940 -0.256
202303 0.551 124.720 0.574
202306 -0.131 125.830 -0.135
202309 -0.097 127.160 -0.099
202312 -0.073 126.450 -0.075
202403 -0.194 128.580 -0.196
202406 -0.080 129.910 -0.080

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProQR Therapeutics NV  (FRA:0PQ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


ProQR Therapeutics NV Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV Business Description

Industry
Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

ProQR Therapeutics NV Headlines

No Headlines